HC016 / Zhejiang Haichang Biotech - LARVOL DELTA

Haichang Biopharma HC016 successfully obtained IND in China and the United States, accelerating the implementation of innovative tumor immunotherapy worldwide [Google translation] (bydrug.pharmcube.com) - "On March 4, 2025, the HC016 lipid complex injection, the world's first TLR9 agonist based on lipid nanoparticle (LNP) delivery technology independently developed by Haichang Bio, officially obtained the clinical trial (IND) approval from the China National Medical Products Administration (NMPA)."

New trial • Oncology • Solid Tumor